Page 32 - HP2017FIN4PRN.indd
P. 32
Sun Pharma Ajanta Pharma
We were pioneers among Indian pharmaceutical companies to see Ajanta Pharma is a specialty pharmaceutical company engaged in
tremendous value in investing in research & development (R&D). Our development, manufacture and marketing of quality finished
early investments in R&D, beginning three decades ago, enabled us to dosages in domestic and international markets. Established in 1973
make technology our key differentiator and develop a basket of robust and headquartered in Mumbai-India, we are committed to 'Serve
products for diverse markets across the world. Our core strength lies in Health Care Needs Worldwide'. Ajanta has been consistently
our ability to excel in developing generics and technologically complex providing high quality affordable medicines to patients in different
products through focused teams in formulations, process chemistry and parts of the world.
analytical development. We have the capability to deliver quality products
within established timelines, at low costs and without compromising on We employ over 5,000 people worldwide and our products are sold
quality. in over 40 countries. Ajanta operates with five state-of-the art
manufacturing facilities that produce high quality pharmaceutical
We have around 2000 research scientists working in multiple R&D products. We focus on commercializing unique generic products and
centres equipped with cutting-edge enabling technologies for research. pioneering synergistic combination products in the therapeutic
Our scientists have expertise in developing generics, difficult to make
technology intensive products, Active Pharmaceutical Ingredients (APIs), areas of anti-malarial, Cardiovascular, dermatology, male erectile
Novel Drug Delivery Systems (NDDS) and New Chemical Entities (NCEs). dysfunction, musculoskeletal, and ophthalmology.
Our capabilities span the development of differentiated products, such In India, we have significant presence in the fast growing specialty
as liposomal products, inhalers, lyophilised injections, nasal sprays, therapeutic segments of Cardiovascular, dermatology,
besides developing controlled release dosage forms. ophthalmology and musculoskeletal. With primary focus on new
Over the years, we have developed expertise and gathered experience in product innovation and introduction, we have been consistently
performing pharmacokinetic and bioequivalence studies to facilitate the identifying unmet medical needs and introducing many
introduction of generic or branded generic drugs into the international first-to-market products to cater to those needs. Our products
market. Our 408-bed clinical pharmacology unit with expert staff works provide patient compliance and convenience over existing
on bioequivalence/bioavailability studies in compliance with GCP. therapeutic options. Gaining first mover advantage, many of our
Facilities include a full-fledged site for Phase I clinical studies. Our CPU brands hold leadership positions in their respective sub- therapeutic
has been audited by US FDA, ANVISA, MHRA, and DCGI among others. segments.
Ajanta has extensive presence in many countries in Asia, Africa and
Latin America with customized product portfolio to suit the needs of
each country. Having successfully gone through USFDA inspection,
we have started commercial operations in the US market in the first
quarter of 2013. With a portfolio of 25 ANDAs which have been filed
with the US FDA, we look forward to the US market to be our key
growth driver in coming years.
23
22 Our Suppliers Portfolio - Hawkary Co. Our Suppliers Portfolio - Hawkary Co. 23
